Unknown

Dataset Information

0

A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.


ABSTRACT:

Background

Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL).

Methods

Forty-four patients with chemo-naïve stage I/II NTCL were enrolled in a prospective, multicenter, phase II study and received six cycles of IMEP (ifosfamide 1.5 g/m(2) on days 1-3; methotrextate 30 mg/m(2) on days 3 and 10; etoposide 100 mg/m(2) on days 1-3; and prednisolone 60 mg/m(2) per day on days 1-5) followed by involved field radiotherapy (IFRT).

Results

Overall response rates were 73% (complete remission [CR] in 11 of 41 evaluable patients [27%]) after IMEP chemotherapy and 78% (CR 18 of 27 evaluable patients [67%]) after IMEP followed by IFRT. Neutropenia and thrombocytopenia were documented in 33 patients (75%) and 7 patients (16%), respectively. Only 8 patients (18%) experienced febrile neutropenia. Three-year progression-free survival (PFS) and overall survival (OS) were 66% and 56%, respectively. High Ki-67 (?70%) and Ann Arbor stage II independently reduced PFS (p = .004) and OS (p = .001), respectively.

Conclusion

Due to the high rate of progression during IMEP chemotherapy, IFRT needs to be introduced earlier. Moreover, active chemotherapy including an l-asparaginase-based regimen should be use to reduce systemic treatment failure in stage I/II NTCL.

SUBMITTER: Kim TM 

PROVIDER: S-EPMC4221378 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.

Kim Tae Min TM   Kim Dong-Wan DW   Kang Yoon-Koo YK   Chung Jooseop J   Song Hong-Suk HS   Kim Hyo Jung HJ   Kim Byung Soo BS   Lee Jong-Seok JS   Kim Hawk H   Yang Sung Hyun SH   Yuh Young Jin YJ   Bae Sung Hwa SH   Hyun Myung Soo MS   Jeon Yoon Kyung YK   Kim Chul Woo CW   Heo Dae Seog DS  

The oncologist 20141003 11


<h4>Background</h4>Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL).<h4>Methods</h4>Forty-four patients with chemo-naïve stage I/II NTCL were enrolled in a prospective, multicenter, phase II study and received six cycles of IMEP (ifosfamide 1.5 g/m(2) on days 1-3; methotrextate 30 mg/m(2) on days 3 and 10; etoposide 100 mg/m(2) on days 1-3; an  ...[more]

Similar Datasets

| S-EPMC6056977 | biostudies-literature
| S-EPMC5704067 | biostudies-literature
| S-EPMC8350702 | biostudies-literature
| S-EPMC5763273 | biostudies-literature
| S-EPMC6476925 | biostudies-literature
| S-EPMC5564839 | biostudies-other
| S-EPMC7317673 | biostudies-literature
| S-EPMC9248758 | biostudies-literature
| S-EPMC8818987 | biostudies-literature
| S-EPMC2793043 | biostudies-literature